Megafine Pharma

Megafine Pharma Private Limited is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. Founded in 1995 by Shailesh Sanghvi, Ashok Jhaveri, and Hasmukh Gandhi, the company has established a long track record in the sector. Based in Mumbai, India, Megafine operates two multipurpose manufacturing facilities in Vapi and Nashik. These sites have received approvals from numerous international regulatory bodies, including the US FDA, EMA EU-GMP (Germany), PMDA (Japan), and Health Canada.

The company's business model focuses on the production of niche, low-volume, high-value APIs that are off-patent. It serves a global client base of drug discovery and generic pharmaceutical companies across more than 40 countries. Megafine's business is primarily order-driven and includes contract manufacturing services, offering production from small to commercial-scale batches. The company has developed expertise in complex products, such as polymorphs and chiral compounds, and is a major manufacturer of Pyrantel Pamoate and Piperazine derivatives.

Megafine's product portfolio covers several therapeutic categories, including Anthelmintic, Cardiology, Urinary Incontinence, and Central Nervous System (CNS) treatments. In February 2025, the private equity arm of Motilal Oswal acquired a majority stake in the company. For the fiscal year ending March 31, 2024, the company's operating revenue was reported to be in the range of INR 300-400 crore.

Keywords: Active Pharmaceutical Ingredients, API manufacturing, advanced intermediates, contract manufacturing, generic drugs, pharmaceutical supplier, chiral chemistry, polymorphs, Pyrantel Pamoate, Piperazine derivatives, Anthelmintic, Cardiology, CNS, Urinary Incontinence, pharmaceutical exports, Vapi, Nashik, drug discovery services, custom synthesis, CDMO